Drug Repurposing for Advanced PC 12. Chloroquine

Thanks. Interestingly, the Rutgers group has three studies in 3 different subsets. 

(1) with docetaxel, among men with mCRPC. Apparently, this study did not meet its goal. It says, "If there are 8 or fewer responses among these 15 patients, we will consider the combination therapy to not be worthy of further study, and stop the trial," and they write, "Lack of improved efficacy compared to historical controls, competing studies." 

(2) hydroxychloroquine alone among men who have a recurrence after initial treatment.  It is ongoing.

(3) hydroxychloroquine with Navitoclax (an investigational agent) and abiraterone after resistance to abiraterone has occurred (mCRPC). They are hoping to reverse the abiraterone resistance.

I hope their results get published in any case.